ImmunoMind helps select the best T-cell therapy candidates early by assessing and comparing their designs with single-cell precision. ImmunoMind's Augmented Intelligence platform is based on proprietary single-cell multi-omics technologies to automatically evaluate 14 essential T-cell population characteristics – exhaustion, persistence, immune profile, and more. The platform guides translational and clinical research to improve the probability of success in later drug development stages.UC Berkeley SkyDeck'20 Alumnus.